Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer.

[1]  John T. Wei,et al.  A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. , 2011, The Journal of urology.

[2]  A. Partin,et al.  ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program. , 2011, Urology.

[3]  A. Partin,et al.  Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Sven Rabung,et al.  [How to deal with missing data?]. , 2010, Psychotherapie, Psychosomatik, medizinische Psychologie.

[5]  Roger Newson,et al.  Comparing the Predictive Powers of Survival Models Using Harrell's C or Somers’ D , 2010 .

[6]  H. Klocker,et al.  Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. , 2010, European urology.

[7]  John T. Wei,et al.  A Prospective, Multicenter, National Cancer Institute Early Detection Research Network Study of [−2]proPSA: Improving Prostate Cancer Detection and Correlating with Cancer Aggressiveness , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[8]  W. Catalona,et al.  [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study. , 2010, The Journal of urology.

[9]  E. Steyerberg,et al.  Is delayed radical prostatectomy in men with low‐risk screen‐detected prostate cancer associated with a higher risk of unfavorable outcomes? , 2010, Cancer.

[10]  A. Partin,et al.  Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. , 2010, The Journal of urology.

[11]  A. Partin,et al.  Pro–Prostate-Specific Antigen Measurements in Serum and Tissue Are Associated with Treatment Necessity among Men Enrolled in Expectant Management for Prostate Cancer , 2009, Clinical Cancer Research.

[12]  B. Trock,et al.  Risk stratification of men choosing surveillance for low risk prostate cancer. , 2009, The Journal of urology.

[13]  J. Epstein,et al.  Change in prostate cancer grade over time in men followed expectantly for stage T1c disease. , 2008, The Journal of urology.

[14]  D. Chan,et al.  [-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. , 2007, The Journal of urology.

[15]  John T. Wei,et al.  Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. , 2006, Journal of the National Cancer Institute.

[16]  B. Trock,et al.  Delayed versus immediate surgical intervention and prostate cancer outcome. , 2006, Journal of the National Cancer Institute.

[17]  Georg Bartsch,et al.  Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. , 2004, The Journal of urology.

[18]  H. Klocker,et al.  Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. , 2003, The Journal of urology.

[19]  D. Chan,et al.  Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml. , 2003, The Journal of urology.

[20]  Stephen D Mikolajczyk,et al.  Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer. , 2003, The Keio journal of medicine.

[21]  Leonard S Marks,et al.  Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease. , 2003, Clinical chemistry.

[22]  H. Klocker,et al.  Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis. , 2003, Urology.

[23]  Jos Twisk,et al.  Attrition in longitudinal studies. How to deal with missing data. , 2002, Journal of clinical epidemiology.

[24]  P. Walsh,et al.  Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. , 2002, The Journal of urology.

[25]  O. Vorm,et al.  Identification of precursor forms of free prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry. , 2001, Cancer research.

[26]  T. Wheeler,et al.  A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. , 2000, Cancer research.

[27]  P. Walsh,et al.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. , 1994, JAMA.

[28]  A. D'Amico,et al.  NCCN clinical practice guidelines in oncology: prostate cancer. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

[29]  Liying Zhang,et al.  Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  R. Newson.  Comparing the predictive power of survival models using Harrell ’ s c or , 2010 .

[31]  Anthony D'Amico,et al.  Prostate cancer. Clinical practice guidelines in oncology. , 2007, Journal of the National Comprehensive Cancer Network : JNCCN.

[32]  L. Fisher,et al.  Time-dependent covariates in the Cox proportional-hazards regression model. , 1999, Annual review of public health.